Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
Date:1/13/2009

NEW YORK, Jan. 13 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc. (BLU: TSX). The full 52-page report can be found at www.crystalra.com.

BELLUS Health Inc. ("BELLUS Health" or "the Company") is a global health company focused on providing innovative pharmaceutical and nutraceutical solutions for critical unmet needs. BELLUS Health aims to generate revenue in the short to medium term through the marketing and sale of branded nutraceutical products, thus enabling the medium- to long-term development and commercialization of its pharmaceutical pipeline. The Company's pharmaceutical products target disorders with no known cures and limited treatments. BELLUS Health's most advanced pharmaceutical candidate is KIACTA(TM) (eprodisate), a Phase III compound to treat Amyloid A (AA) amyloidosis, a disease marked by an accumulation of abnormal proteins that can lead to organ failure and death. In a Phase II/III trial of eprodisate, patients on KIACTA(TM) (eprodisate) had a lower risk of progression of AA amyloidosis-related renal disease and a slower rate of decline in creatinine clearance (a reduction in clearance indicates worsened renal disease). BELLUS Health expects to file a new protocol amendment to the Investigational New Drug (IND) application for the second pivotal Phase III clinical trial of KIACTA(TM) in the first quarter 2009.

The Company's other pharmaceutical developments include NC-503 (eprodisate), which is currently in a proof-of-concept Phase II study in patients with Type II diabetes and certain features of metabolic syndrome, and a prodrug program for Alzheimer's disease (AD), which is at the preclinical development stage. The Company, through its wholly owned subsidiary, OVOS Natural Health Inc., is also commercializing a condition-specific, clinically tested branded nutraceutical to protect memory. This first product, VIVIMIND(TM), was launched in Canada in September 2008 and is also available via the Internet. The Company plans to market VIVIMIND(TM) in the U.S. in 2009 and in the EU in 2011.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of fifty thousand U.S. dollars for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed may constitute forward-looking statements as defined by applicable securities legislation. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the SEC or SEDAR.

These statements and other forward-looking statements involve numerous risks and uncertainties, known and unknown. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited
2. Crystallography reveals the 3-D structure of mammalian sperm receptor
3. Asia Wellness Cruise Offers Crystal Guests Peace of Mind, Body & Spirit
4. Crystalens HD(TM) Receives FDA Approval
5. Success for Crystal Meth Drug Addict on YouTube
6. Steve and Paula Mae Schwartz Honored With Publicity Club of New Englands Crystal Bell Award
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
9. Measurement technique probes surface structure of gold nanocrystals
10. Crystal Light and Mandy Moore Launch Unique Online Wellness Community for Women
11. Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... training, today announced the launch of a new research study, The Business Readiness ... needed to execute that strategy, and the actual success of achieving individual and ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Janet Schloz is still in shock after receiving ... days I’ve had in a long time,” she said. , She thinks the coming week ... that I never thought I would have to help my students.” , The award will ...
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. ... launch of a months-long rebranding effort. This includes the introduction of new packaging ... discussions and market research, we learned that a simple, proactive approach to wellness ...
(Date:3/27/2017)... ... ... The homeowner improvement and repair market is expected to reach $317 billion ... renovations is also on the rise. Per a 2017 report, 13% of all households ... to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not only ...
(Date:3/25/2017)... ... , ... Norland at Swissray is pleased to announce the release of the ELITE ... DXA has an active scan window, which is more than double that of existing bone ... area could not undergo an accurate total body bone density or body composition study. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... The global wound care market was worth $24,482.9 ... of 6.7% during 2016-2022 Among the various wound care products ... the global market in 2015. Among the various applications, surgical wound segment ...
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News Commentary   ... Medical cannabis products around the ... Inc., projects that the global medical cannabis market will reach a value ... is a major market for the new growing industry. By the end ... legally buy and sell medical cannabis. More conservative states like ...
Breaking Medicine Technology: